CWM
ACXP icon

Castle Wealth Management’s Acurx Pharmaceuticals ACXP Stock Holding History

Castle Wealth Management’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-650
Closed -$49K – 669
2022
Q2 		$49K Buy
+650
New +$43.8K 0.03% 216

Other funds holding ACXP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
SFA
Semmax Financial Advisors Winston Salem, North Carolina $388M AUM 14.23% 1-Year Est. Return

Castle Wealth Management's ACXP Position: Q3 2022 in Review

Castle Wealth Management sold out of Acurx Pharmaceuticals (ACXP) in Q3 2022, closing a stake of 650 shares — an estimated $49K sold.

Castle Wealth Management first reported a position in ACXP in Q2 2022 and held it in 1 quarter. The position peaked at $49K in Q2 2022. 14 funds tracked by Wall St. Rank hold ACXP as of Q3 2022.

  • Castle Wealth Management reported no remaining Acurx Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Castle Wealth Management sold 650 Acurx Pharmaceuticals shares in Q3 2022, an estimated $49K.
  • Castle Wealth Management first reported a position in Acurx Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Castle Wealth Management's Acurx Pharmaceuticals position peaked at $49K in Q2 2022.
  • 14 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q3 2022.

Based on Castle Wealth Management's 13F filing for Q3 2022, filed 7 Nov 2022.